Adherence to Treatment In Patients with Chronic Myelogenous Leukemia During a 10-Year Time Period: A Medical Record Review.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1235-1235 ◽  
Author(s):  
Marianne Ulcickas Yood ◽  
Susan A Oliveria ◽  
Ishan Hirji ◽  
Mark Cziraky ◽  
Catherine Davis
Keyword(s):  
Medical Record ◽  
Myelogenous Leukemia ◽  
Medical Record Review ◽  
Imatinib Treatment ◽  
Treatment Information ◽  
Real World Setting ◽  
Time Period ◽  
One Year ◽  
Record Review

Abstract Abstract 1235 Introduction: Over the past 10 years, oral treatment options for chronic myelogenous leukemia (CML) have provided patients autonomy over treatment administration. Low adherence to long-term maintenance therapy is a known challenge in a number of chronic diseases. The correlation between poor adherence and poor clinical outcomes has been previously demonstrated among CML patients in a clinical study setting. Few studies have evaluated adherence to CML treatments in a real-world setting and none have assessed treatment and adherence trends over time in a contemporary cohort of patients. Further, no studies have used medical record review to obtain comprehensive CML diagnosis and treatment information. Method: Medical and pharmacy claims from HealthCore Integrated Research Database™ (8.5 million covered US lives during study time period) were used to identify patients with CML (2001 – 2005). Review of medical records validated diagnosis and treatment exposure. Currently, additional data are being collected on this cohort to extend follow-up through 2010, and expand the number of CML patients to include data on the newer CML treatments. To measure adherence we used medication possession ratio (MPR) (number of days' supply of prescription divided by 365) and treatment interruptions (TI) (failure to refill prescription within 30 days of end of supply from previous prescription or clinician-directed discontinuation). For the current analysis, adherence to imatinib treatment was assessed for one year following treatment initiation. Result: In the initial study time frame (2001-2005), during which imatinib was indicated as first-line treatment, 216 CML patients treated with imatinib were identified. Mean age at imatinib initiation was 51 years and 42.6% were female. Fifty-one percent of patients had a MPR <85% for the one year period after imatinib initiation and 57% of patients experienced at least one TI during the follow up. Conclusion: Our preliminary findings indicate that adherence to imatinib treatment is low in CML patients for the time period studied. This is the first study to use medical record review to validate exposure and adherence by obtaining comprehensive imatinib treatment information on CML patients in a real-world setting and indicates that adherence may be even lower than previously reported. Adherence data from ongoing analyses which includes longer patient follow-up (up to 10 years) and second-generation tyrosine-kinase inhibitors will be presented. Disclosures: Hirji: Bristol-Myers Squibb: Employment. Davis:Bristol-Myers Squibb: Employment.

Comorbidities and Conmedication Use In Patients with Chronic Myelogenous Leukemia.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4492-4492
Author(s):  
Susan A Oliveria ◽  
Marianne Ulcickas Yood ◽  
Ishan Hirji ◽  
Mark Cziraky ◽  
Catherine Davis
Keyword(s):  
Medical Record ◽  
Complete Information ◽  
Myelogenous Leukemia ◽  
Medical Record Review ◽  
Research Database ◽  
Pharmacy Claims ◽  
One Year ◽  
The One ◽  
Record Review

Abstract Abstract 4492 Introduction: Few studies have evaluated the presence of comorbidities and the complexity of conmedication among CML patients in the real-world setting. No studies have used automated claims and medical record review to obtain comprehensive CML diagnosis, treatment, comorbidity, and conmedication information. Methods: Medical and pharmacy claims from HealthCore Integrated Research Database™ (8.5 million covered US lives during study time period) were used to identify patients with CML (2001 – 2005). Information on comorbidities and conmedications was obtained using claims data supplemented with medical record review. For the current analysis, conmedication use and the presence of comorbidities were assessed for one year following imatinib initiation. Results: Two hundred and sixteen CML patients treated with imatinib were included in this analysis. Mean age at imatinib initiation was 51 years and 42.6% were female. The mean number of unique medications for treated patients was 19 (median = 9) in the one-year follow-up. Of all medications prescribed within 1-year of CML treatment initiation, approximately 40% had dosing restrictions (i.e. administration required with/without meals) and dosing of more than once per day. The proportion of patients experiencing 1, 2, 3, and 4+ comorbidities was 22%, 16%, 17%, and 29%, respectively. Analyses were also conducted to explore the complexity (based on dosing guidelines and intake restrictions) of each medication and specific comorbidities. Thirty-four percent % of the conmedications had no intake restrictions while 11% had specific intake restrictions (e.g. take on empty stomach) and 15% had dosing guidelines of more than once per day. Forty-one percent of conmedications had both dosing restrictions and dosing of more than once per day. Conclusion: In addition to their CML diagnosis, patients experience a number of other comorbidities, some of which require complex management regimens. This is the first study to use medical record review to validate exposure and CML diagnosis and use claims and medical record review to obtain comprehensive information on comorbidities and conmedications. Additional data are being collected (and will be presented) on this cohort to extend follow-up through 2010, expand the number of CML patients included, and obtain complete information on all CML treatments and comorbidities. Disclosures: Hirji: Bristol-Myers Squibb: Employment. Davis:Bristol-Myers Squibb: Employment.

Accuracy of Healthcare Worker Recall and Medical Record Review for Identifying Infectious Exposures to Hospitalized Patients

2006 ◽  
Vol 27 (7) ◽  
pp. 722-728 ◽  
Author(s):  
M. Aquino ◽  
J. M. Raboud ◽  
A. McGeer ◽  
K. Green ◽  
R. Chow ◽  
...  
Keyword(s):  
Medical Record ◽  
Healthcare Worker ◽  
Medical Records ◽  
Medical Record Review ◽  
Contact Tracing ◽  
Surgical Intensive Care Unit ◽  
Surgical Intensive Care ◽  
Memory Aids ◽  
Record Review

Objective.To determine the validity of using healthcare worker (HCW) recall of patient interactions and medical record review for contact tracing in a critical care setting.Design.Trained observers recorded the interactions of nurses, respiratory therapists, and service assistants with study patients in a medical-surgical intensive care unit. These observers' records were used as the reference standard to test the criterion validity of using HCW recall data or medical record review data to identify exposure characteristics. We assessed the effects of previous quarantine of the HCW (because of possible exposure) and the availability of patients' medical records for use as memory aids on the accuracy of HCW recall.Setting.A 10-bed medical-surgical intensive care unit at Mount Sinai Hospital in Toronto, Ontario.Patients.Thirty-six HCWs observed caring for 16 patients, for a total of 55 healthcare worker shifts.Results.Recall accuracy was better among HCWs who were provided with patient medical records as memory aids (P<.01). However, HCWs tended to overestimate exposures when they used patient medical records as memory aids. For 6 of 26 procedures or care activities, this tendency to overestimate was statistically significant (P<.05). Most HCWs with true exposures were identified by means of this technique, despite the overestimations. Documentation of the activities of the 4 service assistants could not be found in any of the patients' medical records. Similarly, the interactions between 6 (19%) of 32 other patient–HCW pairs were not recorded in patients' medical records.Conclusions.Data collected from follow-up interviews with HCWs in which they are provided with patient medical records as memory aids should be adequate for contact tracing and for determining exposure histories. Neither follow-up interviews nor medical record review alone provide sufficient data for these purposes.

scholarly journals Medical Record Review to Differentiate between Idiopathic Parkinson’s Disease and Parkinsonism: A Danish Record Linkage Study with 10 Years of Follow-Up

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Lene Wermuth ◽  
Xin Cui ◽  
Naomi Greene ◽  
Eva Schernhammer ◽  
Beate Ritz
Keyword(s):  
Medical Record ◽  
Electronic Medical Records ◽  
Clinical Features ◽  
Medical Records ◽  
Chart Review ◽  
Large Population ◽  
Area Under The Curve ◽  
Medical Record Review ◽  
Record Review

Background. The electronic medical records provide new and unprecedented opportunities for large population-based and clinical studies if valid and reliable diagnoses can be obtained, to determine what information is needed to distinguish idiopathic PD from Parkinsonism in electronic medical records.Methods. Chart review of complete medical records of 2,446 patients with a hospital discharge diagnosis of PD, who, between 1996 and 2009, were registered in the Danish National Hospital Register as idiopathic PD. All patients were examined in neurology departments. Clinical features were abstracted from charts to determine Parkinsonian phenotypes and disease course, using predefined criteria for idiopathic PD.Results. Chart review verified that 2,068 (84.5%) patients met criteria for idiopathic PD. The most distinguishing features of idiopathic PD patients were asymmetric onset, and fewer atypical features at onset or follow-up compared to Parkinsonism, and the area under the curve (AUC) for these items alone is moderate (0.74–0.77) and the highest AUC (0.91) was achieved when using all clinical features recorded in addition to PD medication use and a follow-up of 5 years or more.Conclusion. To reduce disease misclassification, information extracted from medical record review with at least 5 years of follow-up after first diagnosis was key to improve diagnostic accuracy.

scholarly journals Validation of ICD-10-CM codes for injuries complicating pregnancy, childbirth and the puerperium: a medical record review

2021 ◽  
Vol 27 (Suppl 1) ◽  
pp. i9-i12
Author(s):  
Anna Hansen ◽  
Dana Quesinberry ◽  
Peter Akpunonu ◽  
Julia Martin ◽  
Svetla Slavova
Keyword(s):  
Emergency Department ◽  
Medical Record ◽  
International Classification Of Diseases ◽  
Medical Record Review ◽  
Full Sample ◽  
Emergency Department Data ◽  
Classification Of Diseases ◽  
Icd 10 ◽  
Record Review

IntroductionThe purpose of this study was to estimate the positive predictive value (PPV) of International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes for injury, poisoning, physical or sexual assault complicating pregnancy, childbirth and the puerperium (PCP) to capture injury encounters within both hospital and emergency department claims data.MethodsA medical record review was conducted on a sample (n=157) of inpatient and emergency department claims from one Kentucky healthcare system from 2015 to 2017, with any diagnosis in the ICD-10-CM range O9A.2-O9A.4. Study clinicians reviewed medical records for the sampled cases and used an abstraction form to collect information on documented presence of injury and PCP complications. The study estimated the PPVs and the 95% CIs of O9A.2-O9A.4 codes for (1) capturing injuries and (2) capturing injuries complicating PCP.ResultsThe estimated PPV for the codes O9A.2-O9A.4 to identify injury in the full sample was 79.6% (95% CI 73.3% to 85.9%) and the PPV for capturing injuries complicating PCP was 72.0% (95% CI 65.0% to 79.0%). The estimated PPV for an inpatient principal diagnosis O9A.2-O9A.4 to capture injuries was 90.7% (95% CI 82.0% to 99.4%) and the PPV for capturing injuries complicating PCP was 88.4% (95% CI 78.4% to 98.4%). The estimated PPV for any mention of O9A.2-O9A.4 in emergency department data to capture injuries was 95.2% (95% CI 90.6% to 99.9%) and the PPV for capturing injuries complicating PCP was 81.0% (95% CI 72.4% to 89.5%).DiscussionThe O9A.2-O9A.4 codes captured high percentage true injury cases among pregnant and puerperal women.

Sign in / Sign up

Export Citation Format

Share Document